Security Snapshot

BIOMARIN PHARMACEUTICAL INC - Common Stock (BMRN) Institutional Ownership

CUSIP: 09061G101

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

532

Shares (Excl. Options)

187,877,952

Price

$59.43

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
BMRN on Nasdaq
Shares outstanding
192,975,286
Price per share
$56.49
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
187,877,952
Total reported value
$11,153,815,095
% of total 13F portfolios
0.01%
Share change
+8,935,546
Value change
+$560,366,673
Number of holders
532
Price from insider filings
$56.49
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • BMRN - BIOMARIN PHARMACEUTICAL INC - Common Stock is tracked under CUSIP 09061G101.
  • 532 institutions reported positions in Q4 2025.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 532 to 54 between Q4 2025 and Q1 2026.
  • Reported value moved from $11,153,815,095 to $42,115,736.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 532 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 09061G101?
CUSIP 09061G101 identifies BMRN - BIOMARIN PHARMACEUTICAL INC - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of BIOMARIN PHARMACEUTICAL INC - Common Stock (BMRN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 9.1% -15% $1,043,635,432 -$181,821,806 17,560,751 -15% BlackRock, Inc. 31 Dec 2025
PRIMECAP MANAGEMENT CO/CA/ 8.2% $906,812,938 15,795,383 PRIMECAP MANAGEMENT CO/CA/ 30 Jun 2025
Capital Research Global Investors 4.8% -29% $576,308,252 -$241,913,549 9,150,655 -30% Capital Research Global Investors 31 Mar 2025
VIKING GLOBAL INVESTORS LP 4.3% -35% $450,729,215 -$214,821,957 8,322,179 -32% VIKING GLOBAL INVESTORS LP 30 Sep 2025

As of 31 Dec 2025, 532 institutional investors reported holding 187,877,952 shares of BIOMARIN PHARMACEUTICAL INC - Common Stock (BMRN). This represents 97% of the company’s total 192,975,286 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of BIOMARIN PHARMACEUTICAL INC - Common Stock (BMRN) together control 67% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 9.9% 19,135,108 -13% 0.02% $1,137,199,439
VANGUARD GROUP INC 9.4% 18,127,847 -2.4% 0.02% $1,077,337,946
Dodge & Cox 7.6% 14,572,384 -0.78% 0.47% $866,036,781
PRIMECAP MANAGEMENT CO/CA/ 7.5% 14,549,314 -4.5% 0.65% $864,665,732
NORGES BANK 3.9% 7,531,080 0.05% $447,572,084
STATE STREET CORP 3.9% 7,523,218 -14% 0.01% $447,104,846
AQR CAPITAL MANAGEMENT LLC 3.5% 6,686,916 +13% 0.21% $395,196,725
VIKING GLOBAL INVESTORS LP 3.1% 6,036,936 -27% 0.95% $358,775,106
GEODE CAPITAL MANAGEMENT, LLC 1.9% 3,674,089 +3.7% 0.01% $218,394,606
DIMENSIONAL FUND ADVISORS LP 1.7% 3,321,754 +48% 0.04% $197,404,798
MILLENNIUM MANAGEMENT LLC 1.6% 3,037,616 +16% 0.13% $180,525,519
Vestal Point Capital, LP 1.6% 3,000,000 +261% 6.5% $178,290,000
Capital Research Global Investors 1.3% 2,547,287 +0.38% 0.03% $151,385,266
MORGAN STANLEY 1.2% 2,315,620 +68% 0.01% $137,617,375
Deep Track Capital, LP 1.2% 2,300,000 +9153% 3.1% $136,689,000
UBS Group AG 1.1% 2,211,721 +44% 0.03% $131,442,578
FMR LLC 0.95% 1,837,071 +368% 0.01% $109,177,147
Squarepoint Ops LLC 0.95% 1,828,344 +32% 0.22% $108,658,484
NORTHERN TRUST CORP 0.8% 1,547,965 -6.9% 0.01% $91,995,561
AMERIPRISE FINANCIAL INC 0.76% 1,465,198 +19% 0.02% $87,076,480
Qube Research & Technologies Ltd 0.74% 1,436,639 +452% 0.12% $85,379,456
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.74% 1,423,712 +1.9% 0.01% $84,611,204
Assenagon Asset Management S.A. 0.74% 1,419,067 +312% 0.13% $84,335,152
CITADEL ADVISORS LLC 0.71% 1,364,691 +243% 0.06% $81,103,586
DNB Asset Management AS 0.7% 1,359,549 +6.7% 0.28% $80,797,997

Institutional Holders of BIOMARIN PHARMACEUTICAL INC - Common Stock (BMRN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 758,084 $42,115,736 -$7,754,211 $56.49 54
2025 Q4 187,877,952 $11,153,815,095 +$560,366,673 $59.43 532
2025 Q3 179,472,067 $9,720,162,187 -$257,275,980 $54.16 572
2025 Q2 184,517,274 $10,145,314,583 +$90,429,124 $54.97 576
2025 Q1 181,117,177 $12,795,609,480 -$83,582,224 $70.69 576
2024 Q4 183,186,403 $12,041,547,200 +$135,391,046 $65.73 536
2024 Q3 180,328,429 $12,672,555,041 -$377,350,661 $70.29 545
2024 Q2 184,765,128 $15,210,183,330 -$88,804,857 $82.33 555
2024 Q1 186,676,383 $16,305,278,098 +$52,133,744 $87.34 550
2023 Q4 185,955,477 $17,930,401,770 +$422,069,685 $96.42 540
2023 Q3 181,505,269 $16,056,450,996 +$288,283,093 $88.48 513
2023 Q2 178,653,463 $15,494,286,845 -$55,787,524 $86.68 548
2023 Q1 179,051,547 $17,400,388,762 -$352,972,540 $97.24 544
2022 Q4 182,911,512 $18,940,963,403 +$57,088,463 $103.49 570
2022 Q3 182,236,184 $15,455,338,348 +$265,782,383 $84.77 535
2022 Q2 179,167,298 $14,847,543,178 +$141,628,422 $82.87 525
2022 Q1 177,887,694 $13,719,376,304 +$56,012,733 $77.10 543
2021 Q4 177,134,050 $15,645,638,303 +$125,285,951 $88.35 539
2021 Q3 175,999,345 $13,600,848,412 +$49,734,828 $77.29 498
2021 Q2 176,035,547 $14,685,174,801 -$129,382,414 $83.44 510
2021 Q1 177,743,163 $13,419,458,431 -$323,613,922 $75.51 513
2020 Q4 182,409,125 $15,984,411,685 +$294,129,377 $87.69 519
2020 Q3 179,647,602 $13,663,308,058 -$318,133,163 $76.08 487
2020 Q2 180,885,676 $22,304,634,235 +$749,303,824 $123.34 516
2020 Q1 176,765,627 $14,935,321,561 +$286,486,516 $84.50 489
2019 Q4 173,399,113 $14,656,072,034 +$53,952,753 $84.55 454
2019 Q3 173,803,512 $11,713,783,697 -$329,529,601 $67.40 427
2019 Q2 178,061,150 $15,246,971,937 +$229,169,981 $85.65 471
2019 Q1 178,407,022 $15,847,079,543 -$79,141,968 $88.83 475
2018 Q4 179,234,022 $15,261,762,453 -$186,785,701 $85.15 459
2018 Q3 180,913,922 $17,544,279,006 -$163,074,756 $96.97 449
2018 Q2 182,744,905 $17,212,623,295 +$242,791,323 $94.20 440
2018 Q1 180,119,807 $14,603,106,292 +$188,116,053 $81.07 421
2017 Q4 177,577,894 $15,832,679,554 +$224,283,938 $89.17 431
2017 Q3 174,774,741 $16,264,630,184 +$327,519,029 $93.07 407
2017 Q2 171,446,875 $15,566,292,229 +$225,362,433 $90.82 423
2017 Q1 169,058,166 $14,840,823,389 +$900,396,515 $87.78 411
2016 Q4 169,392,815 $14,033,179,313 +$56,824,379 $82.84 404
2016 Q3 168,245,764 $15,561,381,289 +$820,936,102 $92.52 419
2016 Q2 159,820,679 $12,448,675,606 -$243,125,240 $77.80 386
2016 Q1 162,459,664 $13,396,780,263 +$49,991,390 $82.48 379
2015 Q4 161,240,868 $16,892,503,727 +$165,350,997 $104.76 381
2015 Q3 159,382,647 $16,784,552,713 +$116,767,806 $105.32 386
2015 Q2 157,700,975 $21,572,249,632 +$147,538,663 $136.78 390
2015 Q1 156,515,480 $19,500,401,807 +$1,280,160,168 $124.62 374
2014 Q4 147,645,431 $13,350,128,993 +$129,533,927 $90.40 338
2014 Q3 147,667,828 $10,655,377,287 +$238,496,683 $72.16 312
2014 Q2 144,555,723 $8,993,046,726 -$244,244,682 $62.21 319
2014 Q1 148,047,218 $10,094,601,533 +$481,416,489 $68.21 309

Sponsored